At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 78 target
Drug / intervention
Olutasidenib +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b/2 Study of Decitabine and Venetoclax in Combination With the Targeted Mutant IDH1 Inhibitor Olutasidenib
In Brief
A Phase 2 clinical trial evaluating Olutasidenib, Venetoclax, and 2 other interventions for Mutant IDH1 Inhibitor Olutasidenib. Currently recruiting, targeting 78 participants across 3 sites.
Detailed Summary
To find a recommended combination dose of decitabine and venetoclax that can be given in combination with olutasidenib to participants with AML.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMutant IDH1 Inhibitor Olutasidenib
CountriesUnited States
CollaboratorsRigel Pharmaceuticals,Inc.
Timeline
Phase 2Recruiting
20252026202720282029
First PostedJun 2024
Enrollment StartAug 2024
TodayJul 2026
Primary CompletionJun 2027
Study CompletionJun 2029
First PostedJun 6, 2024
Enrollment StartAug 29, 2024
Primary CompletionJun 30, 2027
Study CompletionJun 30, 2029
TodayJul 1, 2026
Enrollment to primary: 2.8 yearsPosted 2.1 years agoPrimary completion in 12 months
Interventions
Olutasidenibdrug
Given by PO
Venetoclaxdrug
Given by PO
Decitabinedrug
Given by IV
Decitabine/cedazuridinedrug
Given by PO